Last week AstraZeneca released the info about their Phase III trial of its COVID-19 vaccine candidate and found that the 2 dose series is 79% effective at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.
Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%. AstraZeneca will continue to analyze the data and prepare for the primary analysis to be submitted to FDA for Emergency Use Authorization in the coming weeks.
It is pretty disappointing that this vaccine has not been authorized yet. It is unclear why they still have not submitted an application to the FDA for emergency use.
